Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5677881 | 0.99 | CHEK1 (0.66) | CHEK1KDR | |
| SCHEMBL5079425 | 0.96 | CHEK1 (0.62) | CHEK1KDR | |
| SCHEMBL142580 | 0.94 | CHEK1 (0.59) | CHEK1KDR | |
| Tert-Butyl Formate SCHEMBL27486793 | 0.91 | CHEK1 (0.57) | CHEK1KDR | |
| SCHEMBL146796 | 0.90 | KDR (0.60) | CHEK1KDR | |
| SCHEMBL5078750 | 0.88 | CHEK1 (0.67) | CHEK1KDR | |
| SCHEMBL5141218 | 0.86 | CHEK1 (0.73) | CHEK1KDR | |
| SCHEMBL144982 | 0.86 | CHEK1 (0.76) | CHEK1KDR | |
| SCHEMBL6313924 | 0.85 | CHEK1 (0.78) | CHEK1KDR | |
| SCHEMBL146578 | 0.85 | CHEK1 (0.61) | CHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | claimed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | claimed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | claimed |
| EP-1496982-A4 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | claimed |
| US-20060093666-A1 | Formulations for tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-05-04 | — | — | US | claimed |
| EP-1610614-A2 | FORMULATIONS FOR TYROSINE KINASE INHIBITORS | Merck & Co. Inc. (US) | 2006-01-04 | — | — | EP | claimed |
| US-6960590-B2 | Orally active salts with tyrosine kinase activity | MERCK & CO. INC. (US) | 2005-11-01 | — | — | US | claimed |
| EP-1328519-B1 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050113577-A1 | Solid forms of slats with tyrosine kinase activity | KARKI SHYAM B (US) | 2005-05-26 | — | — | US | claimed |
| EP-1328519-A4 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2004087651-A2 | FORMULATIONS FOR TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | FRALEY MARK E (US) | 2004-01-01 | — | — | US | claimed |
| US-6656942-B2 | For therapy of diseases such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals | MERCK & CO., INC. | 2003-12-02 | — | — | US | claimed |
| EP-1496982-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-10-30 | — | — | EP | claimed |
| WO-2003088900-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | claimed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | claimed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093666-A1 | Formulations for tyrosine kinase inhibitors | ABL1, ERBB2, JAK1 | CHEK1 554/4885KDR 765/4885 |
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | CHEK1 989/4885KDR 5/4885 |
| US-20080039625-A1 | Screening Methods | CBR3, ZKSCAN2, CRBN | CHEK1 815/4885KDR 1592/4885 |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | CHEK1 989/4885KDR 5/4885 |
| US-20050113577-A1 | Solid forms of slats with tyrosine kinase activity | ROS1, MERTK, LYN | CHEK1 566/4885KDR 30/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CHEK1 499/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.